Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 2,298 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Treatment Response Clear all

Conditions: Alcohol Dependence
Interventions: Alcohol administration; Placebo administration; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Columbia, Maryland

Conditions: Non Small Cell Lung Cancer
Interventions: DCE-MRI scan, Stereotactic Body Radiation Therapy, 4D-CT scan; Other · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Prior Treatment With PD-0325901 With Ongoing Clinical Response
Interventions: PD-0325901; Drug
Lead sponsor: Sharp HealthCare; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Autism Spectrum Disorders
Interventions: Pivotal Response Training; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 4 Years to 35 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Myofascial Pain Syndrome - Lower Back, Myofascial Pain
Interventions: Tuina treatment, Usual care; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Rochester, Minnesota

Conditions: Chronic Musculoskeletal Pain
Interventions: Mind-body emotional awareness program; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Southfield, Michigan

Conditions: Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Olaparib 300mg tablets, Placebo to match olaparib 300mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 16
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions: Dorzolamide-timolol; Drug
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer
Interventions: XL092, Pembrolizumab; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia • Chapel Hill, North Carolina • Philadelphia, Pennsylvania

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 53
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more

Conditions: High Risk Prostate Carcinoma, Prostate Cancer
Interventions: Abiraterone acetate, Prednisone, Hyperpolarized [1-13C] pyruvate (HP 13C), Magnetic Resonance Imaging (MRI), Non-investigational radical prostatectomy (RP), Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT); Drug · Procedure
Lead sponsor: Ivan de Kouchkovsky, MD; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Interventions: Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy; Drug · Procedure
Lead sponsor: Persephone Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: Orange, California • San Diego, California • Miami, Florida + 6 more

Conditions: Kinetoplastid, Skin Diseases, Parasitic, Parasitic Diseases, Leishmaniasis, Protozoa
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: Omega-3 fatty acid, Bovine gelatin capsules; Dietary Supplement · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Pancreatic Cancer
Interventions: Tadalafil, Pembrolizumab, Ipilimumab, CRS-207; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Hyperpolarized 129-Xenon gas, MRI; Drug · Device
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Durham, North Carolina • Madison, Wisconsin

Conditions: Anaemia
Interventions: GSK1278863, Placebo, rhEPO; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Azusa, California • Los Angeles, California • San Dimas, California + 13 more

Conditions: Peripheral T-cell Lymphoma
Interventions: Pralatrexate Injection; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Novi, Michigan • New York, New York

Conditions: Anxiety Disorder of Childhood, Separation Anxiety Disorder of Childhood, Social Anxiety Disorder of Childhood, Generalized Anxiety Disorder
Interventions: Supportive Parenting for Anxious Childhood Emotions, Parent Educational Support, Cognitive-Behavioral Therapy; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 6 Years to 12 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Major Depressive Disorder (MDD)
Interventions: ADT, Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 24
States / cities: Garden Grove, California • Temecula, California • Orlando, Florida + 21 more

Conditions: Glioblastoma Multiforme
Interventions: Not listed
Lead sponsor: New York Presbyterian Brooklyn Methodist Hospital; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Septic Shock, Sepsis, Hypovolemia
Interventions: VBI-S; Drug
Lead sponsor: Vivacelle Bio; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Chandler, Arizona • Tucson, Arizona • Baltimore, Maryland + 5 more

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab [RoActemra/Actemra], methotrexate, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 21
States / cities: Santa Monica, California • Upland, California • Whittier, California + 18 more

Search by objective public record fields.

Biomarkers to Measure Treatment Response for Alcohol Dependence

Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)

A Single Patient IND for PD-0325901

Pivotal Response Treatment for Children With Autism Spectrum Disorders

Magnetic Resonance Elastography to Monitor Response to Manual Therapy in Myofascial Pain

Evaluating a Chronic Pain Treatment Program

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.

H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

Diagnosis and Treatment of Leishmania Infections

Study of Supplementation of Antidepressants With Fish Oil to Improve Time to Clinical Response

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Brain Response Associated With Parent-based Treatment for Childhood Anxiety Disorders

A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

MRI Predictors of Response to Tumor Treating Fields

VBI-S for the Treatment of Hypotension in Hypovolemic Septic Shock Patients

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment